Opioid Dispute Resolution Denied By US FDA In Part Because Of Dueling Requests

Pharmaceutical Manufacturing Research Services argued that its immediate-release oxycodone should be approved with abuse-deterrent labeling while simultaneously asserting that abuse-deterrent labeling should only be permitted based on postmarketing studies, FDA notes.

After receiving a complete response letter (CRL) for its immediate-release (IR) formulation of oxycodone hydrochloride, Pharmaceutical Manufacturing Research Services, Inc. (PMRS) requested a hearing on the US FDA's decision, arguing that the agency should not grant abuse-deterrent claims based on pre-marketing data while simultaneously seeking abuse-deterrent labeling for its own product, the agency say.

But FDA denied the company's request for such a hearing, leaving the sponsor a clear message: You can't have it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Complete Response Letters

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>